Published in Int J Cancer on August 27, 2013
Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer (2014) 1.10
Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Front Oncol (2014) 0.99
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells (2015) 0.97
Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterol Hepatol Bed Bench (2015) 0.94
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol (2016) 0.87
Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer (2015) 0.86
Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology (2015) 0.85
Periostin expression and its prognostic value for colorectal cancer. Int J Mol Sci (2015) 0.84
Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer. Int J Mol Sci (2014) 0.82
Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients. World J Gastroenterol (2014) 0.80
Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients. PLoS One (2014) 0.79
Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Int J Clin Exp Pathol (2015) 0.78
HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. Oncotarget (2014) 0.76
Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. World J Gastroenterol (2015) 0.76
Quantitative detection of the tumor-associated antigen large external antigen in colorectal cancer tissues and cells using quantum dot probe. Int J Nanomedicine (2016) 0.76
A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med (2016) 0.75
Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. Transl Oncol (2016) 0.75
Circulating Oxidized Low-Density Lipoproteins and Antibodies against Oxidized Low-Density Lipoproteins as Potential Biomarkers of Colorectal Cancer. Gastroenterol Res Pract (2015) 0.75
Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers. Biomark Cancer (2017) 0.75
Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen. Cancer Med (2017) 0.75
Correlation of human epidermal growth factor receptor protein expression and colorectal cancer. World J Gastroenterol (2015) 0.75
The Genome-Wide Analysis of Carcinoembryonic Antigen Signaling by Colorectal Cancer Cells Using RNA Sequencing. PLoS One (2016) 0.75
Systematic review: brain metastases from colorectal cancer-Incidence and patient characteristics. BMC Cancer (2016) 0.75
Psychological effects of the intensified follow-up of the CEAwatch trial after treatment for colorectal cancer. PLoS One (2017) 0.75
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol (2008) 7.45
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 5.76
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst (1997) 5.68
Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev (2007) 5.63
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol (2010) 5.10
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med (1996) 4.46
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol (2012) 2.86
American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer (2000) 2.80
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 2.79
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol (2008) 2.65
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest (2005) 2.62
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
[Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam (1968) 2.54
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst (2012) 2.49
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem (2001) 2.48
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.43
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology (2006) 2.34
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer (2010) 2.16
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer (2008) 2.08
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07
TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med (2012) 1.94
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med (2011) 1.93
One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology (2010) 1.91
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst (2009) 1.89
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum (2007) 1.85
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst (2012) 1.83
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol (2009) 1.83
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg (1994) 1.74
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer (2009) 1.74
Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol (2010) 1.72
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol (2010) 1.69
Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med (2011) 1.68
Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol (2008) 1.64
Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol (2010) 1.62
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol (2011) 1.61
Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med (2010) 1.51
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol (2006) 1.51
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol (2012) 1.42
Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ (2004) 1.41
Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg (1997) 1.38
Serum tumour markers: how to order and interpret them. BMJ (2009) 1.37
A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery (1987) 1.35
Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst (2011) 1.33
Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg (1999) 1.32
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev (2012) 1.31
Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol (2009) 1.30
Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum (1998) 1.27
The GIST paradigm: lessons for other kinase-driven cancers. J Pathol (2010) 1.26
Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg (1998) 1.22
CEA serum levels in non-neoplastic disease. Int J Biol Markers (1992) 1.21
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer (2011) 1.19
Targeted therapy for gastric cancer. Curr Treat Options Oncol (2012) 1.19
C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst (2011) 1.16
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol (2001) 1.79
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
Adequate surgery for papillary thyroid cancer. Surgeon (2009) 1.48
Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer (1986) 1.45
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer (1986) 1.44
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer (1994) 1.44
[Thyroid disease in pregnant women and its development after childbirth]. Vnitr Lek (2002) 1.38
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res (2002) 1.36
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol (1997) 1.33
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 1.32
A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg (1995) 1.32
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer (1987) 1.30
The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis (2012) 1.28
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer (1991) 1.25
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol (2001) 1.22
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol (1996) 1.14
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res (2008) 1.14
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res (1992) 1.11
Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther (2001) 1.09
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer (1986) 1.06
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol (2000) 1.02
Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res (1996) 1.01
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res (2009) 0.99
Up-regulation of cyclooxygenase-2 expression in cultured microglia by prostaglandin E2, cyclic AMP and non-steroidal anti-inflammatory drugs. Eur J Neurosci (1997) 0.99
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer (1987) 0.98
Importance of miR-20a expression in prostate cancer tissue. Anticancer Res (2010) 0.98
Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies. Biomed Pharmacother (2005) 0.97
Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res (2010) 0.97
STn and prognosis in breast cancer. Oncology (2001) 0.95
The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood (2001) 0.95
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Br J Cancer (1987) 0.95
Identification of membrane antigens in granulocytes and colonic carcinoma cells by a monoclonal antibody specific for biliary glycoprotein, a member of the carcinoembryonic antigen family. Cancer Lett (1991) 0.95
MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol (1997) 0.94
Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology (2011) 0.94
Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. Int J Cancer (2001) 0.94
Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res (1996) 0.94
Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol (1999) 0.94
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem (2001) 0.94
Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem (1992) 0.93
Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions. Tumour Biol (1988) 0.93
Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer (1996) 0.93
Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factor-kappaB activation in resting and activated microglial cells. J Neurochem (2003) 0.93
Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study. J Clin Oncol (1996) 0.92
Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology (1996) 0.92
Expression of laminin in pancreatic neoplasms and in chronic pancreatitis. Am J Surg Pathol (1984) 0.92
Interferon-gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. J Neurochem (1996) 0.91
Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia. J Neurosci Res (2001) 0.91
Epidermal growth factor receptors and epidermal growth factor-like activity in colorectal mucosa, adenomas and carcinomas. Klin Wochenschr (1989) 0.91
Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 0.91
Effect of intraperitoneal bupivacaine on pain after laparoscopic cholecystectomy. Acta Anaesthesiol Scand (1995) 0.91
Effects of systemic glucocorticoid administration on tenocytes. Biomed Pharmacother (2006) 0.90
Symptomatic atlantoaxial dislocation in Down's syndrome. Ann Neurol (1987) 0.90
Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res (1997) 0.90
MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol (2006) 0.90
[Significance of immunoglobulins for the diagnosis and evaluation of the course of liver diseases]. Klin Wochenschr (1969) 0.90
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
Primary prophylaxis of variceal bleeding in cirrhotic patients: a cohort study. Dig Liver Dis (2008) 0.90
Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol (1995) 0.89
Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res (2009) 0.89
Purification of glucose 6-phosphate dehydrogenase from human erythrocytes. Ital J Biochem (1971) 0.89
Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol (2004) 0.89
Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures. J Neuroimmunol (1998) 0.89
Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol (2006) 0.89
Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology (2004) 0.89
Tenascin-C expression and its prognostic significance in colorectal cancer. Oncology (2008) 0.89
Osteoporosis and biomaterial osteointegration. Biomed Pharmacother (2004) 0.89
Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut (2003) 0.88
Effect of L-lysine and L-arginine on primary osteoblast cultures from normal and osteopenic rats. Biomed Pharmacother (2001) 0.88
New polymers for drug delivery systems in orthopaedics: in vivo biocompatibility evaluation. Biomed Pharmacother (2004) 0.88
A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer. Eur J Surg Oncol (1995) 0.88
Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes (2012) 0.88
Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer (1995) 0.88
Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9. Int J Cancer (1986) 0.88
Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol (1988) 0.87
Cellular fibronectin in serum and plasma: a potential new tumour marker? Br J Cancer (1995) 0.87
Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol (2001) 0.87
Prostaglandin E2 downregulates inducible nitric oxide synthase expression in microglia by increasing cAMP levels. Adv Exp Med Biol (1997) 0.87